المؤلفون: Wong, Sandy W., Bar, Noffar, Victoria Mateos, María, Ribas, Paz, Hansson, Markus, Paris, Laura, Hofmeister, Craig, Rodriguez-Otero, Paula, Aranzazu Bermúdez, Maria, Santoro, Armando, Yee, Andrew J., Creignou, Maria, Encinas, Cristina, Cerchione, Claudio, de la Rubia, Javier, Oriol, Albert, Ferstl, Barbara, Besemer, Britta, Chen, Jinjie, Chung, Alexander, Boss, Isaac W., Gaudy, Allison, LI, Shaoyi, Hsu, Kevin, Godwin, Colin, Burgess, Michael R., San-Miguel, Jesús, Jose Costa, Luciano

المصدر: HemaSphere ; volume 7, issue S3, page e1220745 ; ISSN 2572-9241

الإتاحة: https://doi.org/10.1097/01.hs9.0000970436.12207.45Test

المؤلفون: Díaz González, Álvaro, Avetisyan, Gayane, Garcia-Ruiz, Cristian, Vicente Gil, José, Santiago, Marta, José Domínguez-García, Juan, Llop, Marta, Barragan, Eva, Leonor Senent Peris, Maria, DE LA Rubia, Javier, Cervera, José, Such, Esperanza

المصدر: HemaSphere ; volume 7, issue S3, page e8338249 ; ISSN 2572-9241

الإتاحة: https://doi.org/10.1097/01.hs9.0000976612.83382.49Test

المؤلفون: Dimopoulos, Meletios A., Moreau, Philippe, Augustson, Bradley, Castro, Nelson, Pika, Tomas, Delimpasi, Sosana, De la Rubia, Javier, Maiolino, Angelo, Reiman, Tony, Martinez‐Lopez, Joaquin, Martin, Thomas, Mikhael, Joseph, Yong, Kwee, Risse, Marie‐Laure, Asset, Gaelle, Marion, Sylvia, Hajek, Roman

المساهمون: Sanofi

المصدر: American Journal of Hematology ; volume 98, issue 1 ; ISSN 0361-8609 1096-8652

الإتاحة: https://doi.org/10.1002/ajh.26602Test

المؤلفون: Guerreiro, Manuel, Aguilar‐Gallardo, Cristóbal, Montoro, Juan, Francés‐Gómez, Clara, Latorre, Víctor, Luna, Irene, Planelles, Dolores, Carrasco, María Paz, Gómez, María Dolores, González‐Barberá, Eva María, Aguado, Cristina, Sempere, Amparo, Solves, Pilar, Gómez‐Seguí, Inés, Balaguer‐Rosello, Aitana, Louro, Alberto, Perla, Aurora, Larrea, Luis, Sanz, Jaime, Arbona, Cristina, de la Rubia, Javier, Geller, Ron, Sanz, Miguel Ángel, Sanz, Guillermo, Luis Piñana, José

المساهمون: Fundación General CSIC

المصدر: Transplant Infectious Disease ; volume 23, issue 4 ; ISSN 1398-2273 1399-3062

الوصف: Cellular and humoral response to acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections is on focus of research. We evaluate herein the feasibility of expanding virus‐specific T cells (VST) against SARS‐CoV‐2 ex vivo through a standard protocol proven effective for other viruses. The experiment was performed in three different donors' scenarios: (a) SARS‐CoV‐2 asymptomatic infection/negative serology, (b) SARS‐CoV‐2 symptomatic infection/positive serology, and (c) no history of SARS‐CoV‐2 infection/negative serology. We were able to obtain an expanded VST product from donors 1 and 2 (1.6x and 1.8x increase of baseline VST count, respectively) consisting in CD3 + cells (80.3% and 62.7%, respectively) with CD4 + dominance (60% in both donors). Higher numbers of VST were obtained from the donor 2 as compared to donor 1. T‐cell clonality test showed oligoclonal reproducible peaks on a polyclonal background for both donors. In contrast, VST could be neither expanded nor primed in a donor without evidence of prior infection. This proof‐of‐concept study supports the feasibility of expanding ex vivo SARS‐CoV‐2‐specific VST from blood of convalescent donors. The results raise the question of whether the selection of seropositive donors may be a strategy to obtain cell lines enriched in their SARS‐CoV‐2‐specificity for future adoptive transfer to immunosuppressed patients.

الإتاحة: https://doi.org/10.1111/tid.13602Test

المؤلفون: Alegre, Adrián, de la Rubia, Javier, Sureda Balari, Anna, Encinas Rodríguez, Cristina, Suárez, Alexia, Blanchard, María Jesús, Bargay Lleonart, Joan, Rodríguez‐Otero, Paula, Insunza, Andrés, Palomera, Luis, Peñarrubia, María Jesús, Ríos‐Tamayo, Rafael, Casado Montero, Luis Felipe, González, Marta Sonia, Potamianou, Anna, Couturier, Catherine, Pei, Huiling, Hevia, Henar, Milionis, Iordanis, Gaudig, Maren, Mateos, María‐Victoria

المصدر: HemaSphere ; volume 4, issue 3 ; ISSN 2572-9241 2572-9241

الوصف: Supplemental Digital Content is available in the text

الإتاحة: https://doi.org/10.1097/hs9.0000000000000380Test

المؤلفون: Cejalvo, María J., Legarda, Mario, Abella, Eugenia, Cabezudo, Elena, Encinas, Cristina, García‐Feria, Ana, Gironella, Mercedes, Iñigo, Belén, Martín, Jesús, Ribas, Paz, Ruíz, Mª Ángeles, González, Yolanda, Vicuña, Isabel, Ramírez, Ángel, Fernández, Pascual, de la Rubia, Javier

المصدر: British Journal of Haematology ; volume 190, issue 5 ; ISSN 0007-1048 1365-2141

الإتاحة: https://doi.org/10.1111/bjh.16286Test

المؤلفون: Hulin, Cyrille, de la Rubia, Javier, Dimopoulos, Meletios A., Terpos, Evangelos, Katodritou, Eirini, Hungria, Vania, De Samblanx, Hadewijch, Stoppa, Anne‐Marie, Aagesen, Jesper, Sargin, Deniz, Sioni, Anastasia, Belch, Andrew, Diels, Joris, Olie, Robert A., Robinson, Don, Potamianou, Anna, van de Velde, Helgi, Delforge, Michel

المساهمون: Janssen Global Services, LLC, Millennium Pharmaceuticals, Inc.

المصدر: Health Science Reports ; volume 2, issue 1 ; ISSN 2398-8835 2398-8835

الوصف: Aims Studies have shown that bortezomib retreatment is effective in relapsed/refractory multiple myeloma (MM). The observational, prospective electronic VELCADE ® OBservational Study (eVOBS) study assessed bortezomib‐based therapies for patients with MM in everyday practice. Here, we report on those patients receiving retreatment with bortezomib. Methods Consenting adults scheduled to receive bortezomib for MM were enrolled at 162 sites across Europe, Canada, Brazil, Russia, and Turkey between 2006 and 2010. Retrospective data on prior therapies and prospective observational data after bortezomib initiation were captured electronically at baseline, after every bortezomib cycle, and every 12 weeks after discontinuation or progression. Investigator‐assessed responses and adverse events (AEs) were evaluated. Results Ninety‐six of 873 patients enrolled to eVOBS received bortezomib as first retreatment for progressive disease during the prospective observation period. Median age was 62 years, 53% were male, and median number of prior therapies at retreatment was 4. Overall, 41% of patients initiated bortezomib retreatment in combination with dexamethasone, 16% in combination with lenalidomide, and 21% received monotherapy. Rate of partial response or better (≥PR) was 75% at initial bortezomib therapy, including 44% complete response (CR)/near CR (nCR); at retreatment, ≥PR rate was 46%, including 15% CR/nCR. Median progression‐free survival was 11.4 months (95% confidence interval [CI]: 9.1‐12.7) from start of initial bortezomib treatment and 6.4 months (95% CI: 4.4‐7.2) from start of retreatment. Median overall survival from start of retreatment was 17.6 months (95% CI: 14.4‐23.5). Of the 96 patients retreated with bortezomib, 77% reported an AE. Peripheral neuropathy during bortezomib retreatment occurred in 49% of patients, including 10% grade 3/4. Conclusion These data suggest that retreatment with bortezomib is a feasible option for patients with relapsed/refractory MM.

الإتاحة: https://doi.org/10.1002/hsr2.104Test

المؤلفون: Cibeira, Maria T., Oriol, Albert, Lahuerta, Juan J., Mateos, Maria‐Victoria, de la Rubia, Javier, Hernández, Miguel T., Granell, Miquel, Fernández de Larrea, Carlos, San Miguel, Jesús F., Bladé, Joan

المساهمون: Instituto de Salud Carlos III, Spanish Ministry of Health, FEDER

المصدر: British Journal of Haematology ; volume 170, issue 6, page 804-813 ; ISSN 0007-1048 1365-2141

الوصف: Summary Immunomodulatory drugs have been shown to be of benefit in relapsed/refractory immunoglobulin light‐chain ( AL ) amyloidosis. We designed a prospective, multicentre phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with AL amyloidosis not eligible for autologous stem‐cell transplantation. Twenty‐eight patients were included in the study. Cardiac involvement was present in 23 patients; 14 of them had cardiac stage III . The overall haematological response rate was 46%, including complete and very good partial responses in 25% and 18% of patients respectively. Haematological response was mainly associated with absence of cardiac stage III and lower tumour burden. Organ response was observed in 46% of patients. After a median follow‐up of 24 months, median progression‐free and overall survival have not been reached, both being significantly longer in responders ( P < 0·001 and P = 0·001 respectively). Seventeen patients have discontinued treatment, mostly due to amyloid‐related death, disease progression or lack of response. Only 14% of the patients discontinued treatment due to therapy‐related adverse events. Our results support the efficacy of this regimen, with high quality responses and prolonged survival, as well as its tolerability, in patients with AL amyloidosis not eligible for stem cell transplant and without advanced cardiac involvement (clinicaltrials.gov identifier: NCT01194791).

الإتاحة: https://doi.org/10.1111/bjh.13500Test

المؤلفون: Ocio, Enrique M., Oriol, Albert, Bladé, Joan, Teruel, Ana I., Martín, Jesus, de la Rubia, Javier, Gutiérrez, Norma C., Rodríguez Díaz‐Pavón, José, Martínez González, Sara, Coronado, Cinthya, Fernández‐García, Eva M., Siguero Gómez, Mariano, Fernández‐Teruel, Carlos, San Miguel, Jesus

المصدر: British Journal of Haematology ; volume 172, issue 4, page 625-628 ; ISSN 0007-1048 1365-2141

الإتاحة: https://doi.org/10.1111/bjh.13515Test

المؤلفون: Pascual‐Izquierdo, Cristina, del Rio‐Garma, Julio, de la Rubia, Javier, Viejo, Aurora, Mingot, Eva, Cid, Joan, Solanich, Xavier, Fernández‐Sojo, Jesús, Martín‐Sánchez, Jesús, Hernández, Luis, García‐Gala, José María, Alonso, Nieves, González, Victoria, Oliva, Ana, Gómez‐Seguí, Inés, Goterris, Rosa, Guerra, Luisa, García‐Candel, Faustino, Fernández‐Docampo, Marta, Antelo, María Luisa, Salgado‐Barreira, Ángel, Salinas, Ramón

المصدر: Journal of Clinical Apheresis ; volume 36, issue 4, page 563-573 ; ISSN 0733-2459 1098-1101

الوصف: Background Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease characterized by the presence of anti‐ADAMTS13 autoantibodies. Achieving accurate information on incidence and customary disease management is important to provide appropriate diagnostic and therapeutic resources. The aim of this study was to determine the incidence and outcomes of iTTP in Spain. Study design and methods A cross‐sectional survey was carried out among Spanish hospitals, focused on iTTP patients ≥16 years old attended between 2015 and 2017, and those at follow‐up before that interval. Incidence, prevalence, mortality, refractoriness, exacerbations, treatment complications, relapses, and sequelae were estimated. Results Forty‐two hospitals covering roughly 20 million inhabitants answered the survey and reported 203 episodes (138 newly‐diagnosed and 65 relapses), of which 193 (95.1%) were treated. Incidence was 2.67 (95% CI 1.90‐3.45) patients per million inhabitants per year and prevalence 21.44 (95% CI% 19.10‐23.73) patients per million inhabitants. At diagnosis, ADAMTS13 activity and anti‐ADAMTS13 autoantibody were measured in 97% and 84.3% of reported episodes, respectively. Fifteen patients (7.4%) died as a direct consequence of iTTP, 6 of them before receiving any iTTP‐specific treatment. Thirty‐one (16.1%) of the 193 treated episodes were refractory to plasma exchange and corticosteroids, and 51 (26.4%) suffered at least one exacerbation. Conclusion iTTP incidence and prevalence were somewhat higher than those documented in neighboring countries. Together with data on treatments and outcomes, this information will allow us to better estimate what is needed to improve diagnosis and prognosis of iTTP patients in Spain.

الإتاحة: https://doi.org/10.1002/jca.21894Test